DexCom (NASDAQ:DXCM) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Thursday.
DXCM has been the topic of several other reports. TheStreet lowered shares of DexCom from a “c-” rating to a “d+” rating in a report on Wednesday, October 25th. BidaskClub raised shares of DexCom from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 4th. Morgan Stanley reduced their target price on shares of DexCom from $72.00 to $52.00 and set a “neutral” rating on the stock in a report on Friday, November 3rd. Northland Securities reissued a “hold” rating and set a $50.00 target price on shares of DexCom in a report on Thursday, November 2nd. Finally, Barclays reissued a “hold” rating and set a $60.00 target price on shares of DexCom in a report on Monday, January 8th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $68.50.
Shares of DexCom (DXCM) traded down $0.17 during trading on Thursday, hitting $54.35. 1,100,000 shares of the company traded hands, compared to its average volume of 1,380,000. The company has a market cap of $4,720.00, a price-to-earnings ratio of -95.35 and a beta of 0.21. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84. DexCom has a 12 month low of $42.62 and a 12 month high of $86.32.
Institutional investors and hedge funds have recently bought and sold shares of the stock. American International Group Inc. bought a new position in DexCom during the fourth quarter valued at about $116,000. Advisor Group Inc. grew its position in DexCom by 104.9% during the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after buying an additional 837 shares during the period. Thompson Davis & CO. Inc. bought a new position in DexCom during the fourth quarter valued at about $137,000. Zions Bancorporation grew its position in DexCom by 36,222.2% during the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock valued at $160,000 after buying an additional 3,260 shares during the period. Finally, Toronto Dominion Bank grew its position in DexCom by 251.0% during the third quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock valued at $178,000 after buying an additional 2,608 shares during the period.
TRADEMARK VIOLATION NOTICE: This report was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/11/dexcom-dxcm-downgraded-by-valuengine.html.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.